Verici Dx Plc (GB:VRCI) has released an update.
Verici Dx Plc, an innovator in transplant diagnostics, reports a surge in revenues to $3.3m for the first half of 2024, driven by licensing, direct sales, and service income, marking a significant leap from the previous year’s $1.0m. The company has made considerable progress with their lead products, including Tutivia™, and secured key accreditations and collaborations, enhancing their capabilities and outreach. With a strong cash position and a strategic outlook, Verici Dx is set on advancing growth initiatives and maintaining financial discipline into 2026.
For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.
